Bispecific antibodies (bsAbs) are engineered to target 2 different epitopes simultaneously. About 75% of the 16 clinically ...

The partnership aims to expedite the creation of precise treatments to improve results for solid tumour patients.

Global Bispecific Antibody Market Size Bispecific Antibodies Sales FDA Approved Bispecific Antibodies Market Forecast ...

Wuhan YZY Biopharma Co. Ltd. is out-licensing lead candidate M-701, a CD3/EpCAM bispecific antibody, to Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ) for China rights in a deal worth up to ...

BioAtla faces a tight cash runway until Q3 2025, raising concerns about dilution and short-term stock headwinds. Find out why ...

During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to ...

Triveni Bio has roped in $115 million in series B funds to advance preclinical antibody programs designed to treat ...

ImmunoPrecise Antibodies, an AI-driven biotherapeutic research and technology company, has entered into a material transfer and evaluation agreement (MTEA) with Biotheus on bispecific antibodies ...

BioAtla, Inc. faces financial challenges but presents promising pipeline projects in cancer treatment, offering opportunities ...

Ajai Chari, MD, covered both recent FDA approvals and pipeline products, such as non-BCMA chimeric antigen receptor (CAR) ...

A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentation has concluded. About BioAtla®, Inc.